DelveInsight’s, “Recurrent anaplastic astrocytomas – Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Recurrent anaplastic astrocytomas pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Recurrent anaplastic astrocytomas Understanding
Recurrent anaplastic astrocytomas: Overview
Anaplastic astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes. The symptoms of anaplastic astrocytoma vary depending upon the exact location and size of the tumor. Most symptoms result from increased pressure within the brain. An anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. Symptoms commonly associated with anaplastic astrocytomas include headaches, lethargy or drowsiness, vomiting, and changes in personality or mental status. In some cases, seizures, vision problems, weakness of the arms and legs resulting in coordination difficulties may also occur. The exact cause of anaplastic astrocytomas is unknown. Researchers speculate that genetic and immunologic abnormalities, environmental factors (e.g., exposure to ultraviolet rays, certain chemicals, ionizing radiation), diet, stress, and/or other factors may play contributing roles in causing specific types of cancer. A diagnosis of anaplastic astrocytoma is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of imaging techniques including computerized tomography (CT) scanning and magnetic resonance imaging (MRI). The three main forms of treatment for anaplastic astrocytoma are surgery, radiation and chemotherapy. These treatments may be used alone or in combination with one another. The initial treatment in most cases is surgical excision and removal of as much as the tumor as possible (resection).
""Recurrent anaplastic astrocytomas - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recurrent anaplastic astrocytomas pipeline landscape is provided which includes the disease overview and Recurrent anaplastic astrocytomas treatment guidelines. The assessment part of the report embraces, in depth Recurrent anaplastic astrocytomas commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent anaplastic astrocytomas collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
• The companies and academics are working to assess challenges and seek opportunities that could influence Recurrent anaplastic astrocytomas R&D. The therapies under development are focused on novel approaches to treat/improve Recurrent anaplastic astrocytomas.
Recurrent anaplastic astrocytomas Emerging Drugs Chapters
This segment of the Recurrent anaplastic astrocytomas report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Recurrent anaplastic astrocytomas Emerging Drugs
• Eflornithine: Orbus Therapeutics
Eflornithine (α-difluoromethylornithine or DFMO) is an orally bioavailable small molecule. Eflornithine is an irreversible inhibitor of ornithine decarboxylase (ODC) that presents a cytostatic effect in rapidly dividing cells. By inhibiting this enzyme, eflornithine has been shown to slow or delay tumor growth, and has shown activity in certain cancers, including AA. Eflornithine is approved by FDA in intravenous form to treat patients with African trypanosomiasis (sleeping sickness) and was subsequently approved by FDA in a topical form to treat patients with excessive facial hair, or hirsutism. Orbus Therapeutics intends to develop and commercialize eflornithine in North America. The drug is currently being evaluated in Phase III clinical trial to treat recurrent anaplastic astrocytomas.
Further product details are provided in the report……..
Recurrent anaplastic astrocytomas: Therapeutic Assessment
This segment of the report provides insights about the different Recurrent anaplastic astrocytomas drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Recurrent anaplastic astrocytomas
There are approx. 6+ key companies which are developing the therapies for Recurrent anaplastic astrocytomas. The companies which have their Recurrent anaplastic astrocytomas drug candidates in the most advanced stage, i.e. Phase III include, Orbus Therapeutics.
DelveInsight’s report covers around 6+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Recurrent anaplastic astrocytomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Recurrent anaplastic astrocytomas: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Recurrent anaplastic astrocytomas therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Recurrent anaplastic astrocytomas drugs.
Recurrent anaplastic astrocytomas Report Insights
• Recurrent anaplastic astrocytomas Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Recurrent anaplastic astrocytomas Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Recurrent anaplastic astrocytomas drugs?
• How many Recurrent anaplastic astrocytomas drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Recurrent anaplastic astrocytomas?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Recurrent anaplastic astrocytomas therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Recurrent anaplastic astrocytomas and their status?
• What are the key designations that have been granted to the emerging drugs?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook